Soligenix Company Profile (NASDAQ:SNGX)

About Soligenix (NASDAQ:SNGX)

Soligenix logoSoligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SNGX
  • CUSIP: N/A
  • Web:
  • Market Cap: $11.85 million
  • Outstanding Shares: 5,723,000
Average Prices:
  • 50 Day Moving Avg: $2.27
  • 200 Day Moving Avg: $2.44
  • 52 Week Range: $2.02 - $14.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.41
  • P/E Growth: -1.47
Sales & Book Value:
  • Annual Revenue: $6.98 million
  • Price / Sales: 1.70
  • Book Value: $0.64 per share
  • Price / Book: 3.23
  • EBIDTA: ($6,760,000.00)
  • Net Margins: -86.15%
  • Return on Equity: -129.88%
  • Return on Assets: -74.33%
  • Current Ratio: 2.11%
  • Quick Ratio: 3.19%
  • Average Volume: 188,656 shs.
  • Beta: 2.31
  • Short Ratio: 4.96

Frequently Asked Questions for Soligenix (NASDAQ:SNGX)

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How were Soligenix's earnings last quarter?

Soligenix Inc. (NASDAQ:SNGX) announced its quarterly earnings data on Friday, August, 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.09. The business earned $1 million during the quarter, compared to analyst estimates of $1.43 million. Soligenix had a negative net margin of 86.15% and a negative return on equity of 129.88%. View Soligenix's Earnings History.

When will Soligenix make its next earnings announcement?

Soligenix is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Soligenix.

Where is Soligenix's stock going? Where will Soligenix's stock price be in 2017?

3 brokerages have issued 12-month target prices for Soligenix's stock. Their forecasts range from $5.00 to $11.00. On average, they expect Soligenix's stock price to reach $7.33 in the next twelve months. View Analyst Ratings for Soligenix.

Who are some of Soligenix's key competitors?

Who owns Soligenix stock?

Soligenix's stock is owned by many different of institutional and retail investors. Top institutional investors include KIRK RANDAL J (6.30%) and KIRK RANDAL J (4.90%). Company insiders that own Soligenix stock include Christopher J Schaber, Jerome B Zeldis, Marco Maria Brughera and Randal J Kirk. View Institutional Ownership Trends for Soligenix.

How do I buy Soligenix stock?

Shares of Soligenix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soligenix's stock price today?

One share of Soligenix stock can currently be purchased for approximately $2.07.

MarketBeat Community Rating for Soligenix (NASDAQ SNGX)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Soligenix (NASDAQ:SNGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.33 (254.27% upside)

Analysts' Ratings History for Soligenix (NASDAQ:SNGX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017HC WainwrightSet Price TargetBuy$11.00HighView Rating Details
8/14/2017Maxim GroupBoost Price TargetBuy -> Buy$4.00 -> $5.00HighView Rating Details
9/7/2016AegisInitiated CoverageBuy$6.00N/AView Rating Details
11/15/2015Brean CapitalReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 8/18/2015 forward)


Earnings History for Soligenix (NASDAQ:SNGX)
Earnings by Quarter for Soligenix (NASDAQ:SNGX)
Earnings History by Quarter for Soligenix (NASDAQ SNGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/2017Q2 2017($0.32)($0.41)$1.43 million$1.00 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.30)($0.32)$1.30 millionViewN/AView Earnings Details
3/24/2016Q1($0.06)($0.04)$1.00 million$2.97 millionViewN/AView Earnings Details
8/12/2015($0.10)($0.15)$1.00 million$1.10 millionViewN/AView Earnings Details
3/24/2015($0.10)($0.07)$0.80 million$1.93 millionViewN/AView Earnings Details
11/10/2014($0.09)($0.08)$1.51 million$2.79 millionViewN/AView Earnings Details
8/11/2014($0.09)($0.05)$0.80 million$1.40 millionViewN/AView Earnings Details
5/12/2014($0.09)($0.08)$0.80 million$0.90 millionViewN/AView Earnings Details
3/26/2014($0.08)$0.13ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Soligenix (NASDAQ:SNGX)
Current Year EPS Consensus Estimate: $-1.48 EPS
Next Year EPS Consensus Estimate: $-1.47 EPS


Dividend History for Soligenix (NASDAQ:SNGX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Soligenix (NASDAQ:SNGX)
Insider Ownership Percentage: 5.03%
Institutional Ownership Percentage: 8.77%
Insider Trades by Quarter for Soligenix (NASDAQ:SNGX)
Institutional Ownership by Quarter for Soligenix (NASDAQ:SNGX)
Insider Trades by Quarter for Soligenix (NASDAQ:SNGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/8/2017Randal J KirkMajor ShareholderSell160,968$3.12$502,220.16View SEC Filing  
12/16/2016Christopher J SchaberCEOBuy15,804$3.16$49,940.64View SEC Filing  
12/16/2016Marco Maria BrugheraDirectorBuy2,000$3.16$6,320.00View SEC Filing  
12/23/2015Jerome B ZeldisDirectorBuy2,500$1.27$3,175.00View SEC Filing  
12/22/2015Christopher J SchaberCEOBuy10,000$1.29$12,900.00View SEC Filing  
12/22/2014Joseph Michael WaruszCFOBuy8,265$1.21$10,000.65View SEC Filing  
6/25/2013Christopher J SchaberCEOBuy9,523$1.05$9,999.15View SEC Filing  
6/25/2013Keith L BrownlieDirectorBuy19,047$1.05$19,999.35View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Soligenix (NASDAQ:SNGX)
Latest Headlines for Soligenix (NASDAQ:SNGX)
DateHeadline logoSoligenix Inc. (NASDAQ:SNGX) Issues Quarterly Earnings Results - August 12 at 10:40 AM logo$1.43 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter - August 6 at 7:11 AM logo Brokerages Expect Soligenix Inc. (NASDAQ:SNGX) Will Announce Earnings of -$0.33 Per Share - August 4 at 6:26 PM logoSoligenix Begins Patient Enrollment for Pivotal Phase 3 Trial (SGX942) for Oral Mucositis & Enrollment in Phase III of SGX301 ongoing - August 2 at 4:38 PM logoTechnical Reports on Biotech Equities -- BioDelivery Sciences, BioLine Rx, Benitec Biopharma, and Soligenix - August 1 at 4:02 PM logoSoligenix Inc. (SNGX) PT Set at $11.00 by HC Wainwright - July 27 at 10:14 AM logoMid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide - July 19 at 1:47 AM logoMid-Morning Market Update: Markets Edge Higher; BlackRock Profit Misses Views - July 18 at 8:19 AM logoMaxim Group Reaffirms "Buy" Rating for Soligenix Inc. (SNGX) - June 19 at 1:32 PM logoSoligenix, Inc. (SNGX) tp Present Complete Efficacy & Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial - June 19 at 9:35 AM logoComplete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference - June 19 at 9:35 AM logoWhat Biotech Offers a Better Risk/Reward Profile than Soligenix (SNGX)? In Our View, None - June 7 at 10:51 AM logoMaxim Group Analysts Give Soligenix, Inc. (SNGX) a $4.00 Price Target - May 23 at 6:58 PM logoSoligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients - May 18 at 1:03 PM logoSoligenix, Inc. (SNGX) PT Set at $4.00 by Maxim Group - May 13 at 6:26 PM logoSoligenix, Inc. (SNGX) Announces Earnings Results, Misses Expectations By $0.02 EPS - May 12 at 12:38 PM logoWith Two Phase III Trials Operational & Significant Financial Leverage, Soligenix Shining - May 10 at 8:11 PM logoSoligenix Receives Japanese Patent for ThermoVax® Vaccine Heat Stabilization Platform Technology - May 9 at 10:25 AM logoRandal J. Kirk Sells 160,968 Shares of Soligenix, Inc. (SNGX) Stock - May 8 at 7:37 PM logoSoligenix, Inc. (SNGX) Given a $4.00 Price Target at Maxim Group - May 4 at 1:18 AM logoSoligenix, Inc. (SNGX) Announces FDA Protocol Clearance of Pivotal Phase 3 Trial of SGX942 to Treat Oral Mucositis in HNC - May 3 at 11:05 PM logoSoligenix Inc. (SNGX) Has Surged To Over A 5-Month High - April 20 at 12:53 AM logoSoligenix, Inc. (SNGX) Says Results from Ricin Toxin Vaccine Program to be Presented at Conference on Vaccine Research - April 20 at 12:53 AM logoEfficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research - April 19 at 9:13 AM logoSoligenix to Present at the World Orphan Drug Congress - April 12 at 1:01 PM logoFY2017 Earnings Forecast for Soligenix, Inc. Issued By Zacks Investment Research (SNGX) - March 31 at 12:47 PM logoAnalysts Set Expectations for Soligenix, Inc.'s FY2020 Earnings (SNGX) - March 30 at 1:52 PM logoSoligenix Announces Recent Accomplishments And Year-End 2016 Financial Results - March 27 at 9:07 AM logoSoligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting - March 10 at 8:10 AM logoSOLIGENIX, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibits - March 7 at 4:36 PM logoSoligenix to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference - February 2 at 7:00 AM logoTechnical Data and the Price Movement -- Analyst Review of Praxsyn, Baristas Coffee Company, Soligenix and Acacia Diversified Holdings - February 1 at 9:20 AM logo7:09 am Soligenix provides 2016 business outlook and preliminary results dates - January 26 at 7:09 AM logoSoligenix Provides 2016 Business Outlook - January 26 at 7:00 AM logoMarket Influences That Drive Equities Forward - New Research on American Green, Praxsyn, Norsk Hydro and Soligenix - January 21 at 9:03 AM logoSOLIGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - January 7 at 6:07 AM logoSNGX has been busy in 2015 to advance its clinical programs. - January 5 at 10:30 AM logoVista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00 - December 18 at 9:00 AM logoSNGX: Soligenix Reports Positive Preliminary Results from Phase II Study of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients - December 16 at 12:45 PM logoSNGX: Soligenix Initiates Pivotal Phase III Clinical Trial of SGX301 for CTCL - December 14 at 9:55 AM



Soligenix (SNGX) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by Staff